Corvus Pharmaceuticals, Inc.
CRVS
$6.93
-$0.32-4.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -152.64% | 225.43% | 69.88% | -843.62% | 25.24% |
| Total Depreciation and Amortization | 31.82% | 10.00% | -4.76% | 0.00% | -8.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 97.03% | -564.52% | -84.92% | 4,954.24% | -330.13% |
| Change in Net Operating Assets | 1,803.29% | 110.42% | -1,157.25% | 125.32% | -348.86% |
| Cash from Operations | 30.09% | 2.39% | -33.92% | -15.33% | -6.28% |
| Capital Expenditure | -213.89% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -571.79% | 170.29% | -56.50% | 77.78% | -249,957.14% |
| Cash from Investing | -578.46% | 169.75% | -56.38% | 77.78% | -249,957.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12,720.79% | -98.50% | 37,116.00% | -99.70% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Financing | 12,720.79% | -98.50% | 37,116.00% | -99.84% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 359.08% | -192.14% | 139.96% | -237.59% | 243.01% |